Professor Lustig’s Hateful - Grateful 8, follow up Q & A (with slightly improved audio)

12 Jun 2023 · 28 min
28:01

This is a transcript of a June 12, 2023 follow-up Q&A between Dr. Ron Najafi and Dr. (Professor) Robert Lustig about metabolic disease drivers and clinical implications. Lustig emphasizes that type 2 diabetes in children is a recent and growing phenomenon tied to environmental exposures — principally ultra-processed foods and added sugars (fructose). He challenges older medical teaching that type 2 is an untreatable genetic, unrelenting disease and reviews biomarkers (waist circumference, fasting insulin, uric acid, ALT) and imaging for distinguishing metabolically healthy vs unhealthy obesity. He critiques widespread statin use for primary prevention (supports statins for secondary prevention), discusses statins’ mitochondrial effects and associated ~20% increased diabetes risk, and gives practical dietary guidance (treat dessert as occasional — e.g., once/week; whole fruit preferred to juiced/blended). The transcript also links hyperinsulinemia to increased cancer risk and explains why artificial sweeteners may still provoke insulin responses.

Questions this video answers

Around 1992 (he graduated medical school in 1980; first faculty job ~1990).

From about 1 in 600 children to about 1 in 400 (≈50% increase).

In 1975, ~2.5% of adults over age 65 had type 2 diabetes; today ~9.4% of all adults over age 20 have type 2 diabetes (as stated).

About one third of all diabetes diagnoses in children are type 2 (as stated).

Fasting insulin should be <10 μU/mL and optimally <5; ≥15 μU/mL indicates a problem (as stated).

Chapters

More from Dr.

youtube.com

Hippocrates said, let thy food be thy medicine #obesity #metabolicsyndrome #lustig #shorts #health

11mo ago
youtube.com

Robert Lustig, MD: Everything You Know About Obesity Is Wrong

11mo ago
youtube.com

What is the latest on Ozempic and Ozempic like drugs #ozempic #glp1

11mo ago
youtube.com

Bill Wilson, MD: Why GLP-1 Drugs Are Overpriced—and How Compounding and Competition Could Fix It

11mo ago
youtu.be

Nitrosamine in Pharmaceutical Products? A Deep Dive into Risk Management by Ron Najafi, Ph.D.

11mo ago
youtube.com

The Subcellular Processes That Belie All Chronic Disease. The Hateful (or Grateful) Eight #lustig

11mo ago
youtube.com

Bill Wilson, MD: GLPs May Reverse Carb Syndrome—Helping Patients Reach Zero and Sustain with Diet

1y ago
youtube.com

Why Everything You Knew About Obesity Is Wrong | Dr. Robert Lustig on Sugar & Metabolic Syndrome

1y ago
youtube.com

Robert Lustig, MD: How Fructose Fuels Fatty Liver, Oxidative Stress, and Metabolic Disease #fructose

1y ago
youtube.com

Robert Lustig, MD: The 3 Types of Fat Fueling Insulin Resistance and Disease #insulin resistance

1y ago
youtube.com

Bill Wilson, MD: GLPs May Reverse CARB Syndrome. Helping Patients Reach Zero and Sustain with Diet

1y ago
See all content